Health Catalyst (HCAT) Stock Overview
Provides data and analytics technology and services to healthcare organizations in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HCAT Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Health Catalyst, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.20 |
| 52 Week High | US$4.12 |
| 52 Week Low | US$0.96 |
| Beta | 1.57 |
| 1 Month Change | 26.07% |
| 3 Month Change | 117.82% |
| 1 Year Change | -45.41% |
| 3 Year Change | -82.27% |
| 5 Year Change | -95.99% |
| Change since IPO | -94.38% |
Recent News & Updates
Narrative Update • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.
Narrative Update • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.
Narrative Update • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.Recent updates
Narrative Update • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.Narrative Update • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.Narrative Update • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.Narrative Update • May 09
HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.Narrative Update • Apr 24
HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further
Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.Narrative Update • Apr 08
HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.Narrative Update • Mar 25
HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound
Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.Narrative Update • Mar 11
HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.Narrative Update • Feb 24
HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential
Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.Analysis Article • Feb 13
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...Narrative Update • Feb 10
HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.Narrative Update • Jan 27
HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential
Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.Narrative Update • Jan 10
HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.Narrative Update • Dec 26
HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.Narrative Update • Dec 11
HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential
Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.Narrative Update • Nov 27
HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook
Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.Narrative Update • Nov 13
HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance
Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.Analysis Article • Oct 28
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...Narrative Update • Aug 30
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.Analysis Article • Aug 13
Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price
NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...Narrative Update • Aug 10
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.Analysis Article • Aug 04
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jun 10
Health Catalyst: Ignite Platform Is A Growth Catalyst
Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking AlphaAnalysis Article • May 09
Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
New Narrative • Mar 30
Ignite Transition And Recent Acquisitions Will Expand Global Footprint
Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.Seeking Alpha • Mar 25
Health Catalyst: Share Price Continues To Dismiss Positive Earnings And Improved Outlook
Summary Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers. Risks include potential revenue stall, macroeconomic challenges, and stock price volatility, but I remain cautiously optimistic, looking for a breakout to add to my position. Read the full article on Seeking AlphaAnalysis Article • Mar 08
Take Care Before Jumping Onto Health Catalyst, Inc. (NASDAQ:HCAT) Even Though It's 27% Cheaper
To the annoyance of some shareholders, Health Catalyst, Inc. ( NASDAQ:HCAT ) shares are down a considerable 27% in the...Analysis Article • Feb 27
Health Catalyst (NASDAQ:HCAT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| HCAT | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 6.3% | 0.6% | -0.4% |
| 1Y | -45.4% | -38.7% | 18.4% |
Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned -36.1% over the past year.
Return vs Market: HCAT underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| HCAT volatility | |
|---|---|
| HCAT Average Weekly Movement | 17.4% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HCAT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HCAT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,200 | Ben Albert | www.healthcatalyst.com |
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics.
Health Catalyst, Inc. Fundamentals Summary
| HCAT fundamental statistics | |
|---|---|
| Market cap | US$167.74m |
| Earnings (TTM) | -US$265.26m |
| Revenue (TTM) | US$302.48m |
0.5x
P/S Ratio-0.6x
P/E RatioIs HCAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCAT income statement (TTM) | |
|---|---|
| Revenue | US$302.48m |
| Cost of Revenue | US$149.90m |
| Gross Profit | US$152.58m |
| Other Expenses | US$417.83m |
| Earnings | -US$265.26m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.59 |
| Gross Margin | 50.44% |
| Net Profit Margin | -87.69% |
| Debt/Equity Ratio | 111.0% |
How did HCAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 18:58 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Health Catalyst, Inc. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |